154 335

Cited 29 times in

A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma.

Authors
Woo, HY; Bae, SH; Park, JY; Han, KH; Chun, HJ; Choi, BG; Im, HU; Choi, JY; Yoon, SK; Cheong, JY; Cho, SW; Jang, BK; Hwang, JS; Kim, SG; Kim, YS; Seo, YS; Yim, HJ; Um, SH
Citation
Cancer chemotherapy and pharmacology, 65(2):373-382, 2010
Journal Title
Cancer chemotherapy and pharmacology
ISSN
0344-57041432-0843
Abstract
PURPOSE: Hepatic arterial infusion chemotherapy (HAIC) has been reported to be effective in patients with advanced hepatocellular carcinoma (HCC). METHODS: In this multicenter, prospective, open-labeled, clinical trial, we randomly assigned 68 patients with advanced HCC to receive either low-dose [n = 32, 5-fluorouracil (FU), 170 mg/m(2) and cisplatin, 7 mg/m(2) on days 1-5] or high-dose HAIC (n = 36, 5-FU, 500 mg/m(2) on days 1-3 and cisplatin, 60 mg/m(2) on day 2) every 4 weeks via an implantable port system. RESULTS: A total of 207 cycles of HAIC was given to the 68 patients. Overall, 6 patients (8.8%) achieved a partial response and 21 patients (30.9%) had stable disease. The objective response rate (CR + PR) was significantly improved in the high-dose group compared to the low-dose group (16.7% vs. 0%, P = 0.024). The median time to disease progression and overall survival were slightly prolonged in the high-dose group compared to the low-dose group (median survival, 193 vs. 153 days; P = 0.108; median time to disease progression, 145 vs. 90 days; P = 0.095). Multivariate analysis showed that tumor response to treatment [P = 0.007, RR 2.27 (95% CI, 1.248-4.132)] was the only factor associated with overall survival. All adverse events were tolerable and successfully managed in both treatment groups. CONCLUSIONS: Both HAIC regimens are safe and effective in patients with advanced HCC. High-dose HAIC achieves a better tumor response compared to low-dose HAIC.
MeSH terms
AdultAgedAntineoplastic Combined Chemotherapy Protocols/administration & dosage/adverseCarcinoma, Hepatocellular/*drug therapy/mortality/pathologyCisplatin/administration & dosageDrug Administration ScheduleFemaleFluorouracil/administration & dosageHepatic ArteryHumansInfusions, Intra-ArterialLiver Neoplasms/*drug therapy/mortality/pathologyMaleMiddle AgedPrognosisProspective StudiesSurvival Rate
DOI
10.1007/s00280-009-1126-2
PMID
19763572
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
AJOU Authors
정재연조성원
Files in This Item:
Full-Text Not Available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse